Abstract
During the process of tumorigenesis, certain cancers are known to develop deficiencies in one or more major pathways of DNA damage repair, rendering them critically dependent on alternative repair processes for maintaining genomic integrity and viability. Targeting these alternative DNA repair mechanisms is a potentially highly-specific anticancer strategy, as their inhibition is theoretically toxic only to tumor cells and not to normal tissues. We will review here the rationale behind this strategy and provide examples of its application. We will also discuss several as yet unanswered questions surrounding this strategy, including whether human cancers frequently harbor synthetically lethal interactions in DNA repair and, if so, how patients might be identified who would benefit from targeting such interactions.
Keywords: Radiation, chemotherapy, DNA repair, double-strand break repair, non-homologous end joining, homologous recombination, Tumorigenesis, Homologous recobmination, Mutation, Tumor-specific phenotype, PARP inhibitor, BRCA-defective tumors, Translocation, Genetic mutation, Amplification, Oncogenic stress, Cytotoxic drugs, Radiomimetics, NHEJ, PARP proteins, PARP inhibitors, Biomarkers, Oncology
Current Drug Targets
Title: Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Volume: 11 Issue: 10
Author(s): Benjamin J. Moeller, Wadih Arap and Renata Pasqualini
Affiliation:
Keywords: Radiation, chemotherapy, DNA repair, double-strand break repair, non-homologous end joining, homologous recombination, Tumorigenesis, Homologous recobmination, Mutation, Tumor-specific phenotype, PARP inhibitor, BRCA-defective tumors, Translocation, Genetic mutation, Amplification, Oncogenic stress, Cytotoxic drugs, Radiomimetics, NHEJ, PARP proteins, PARP inhibitors, Biomarkers, Oncology
Abstract: During the process of tumorigenesis, certain cancers are known to develop deficiencies in one or more major pathways of DNA damage repair, rendering them critically dependent on alternative repair processes for maintaining genomic integrity and viability. Targeting these alternative DNA repair mechanisms is a potentially highly-specific anticancer strategy, as their inhibition is theoretically toxic only to tumor cells and not to normal tissues. We will review here the rationale behind this strategy and provide examples of its application. We will also discuss several as yet unanswered questions surrounding this strategy, including whether human cancers frequently harbor synthetically lethal interactions in DNA repair and, if so, how patients might be identified who would benefit from targeting such interactions.
Export Options
About this article
Cite this article as:
J. Moeller Benjamin, Arap Wadih and Pasqualini Renata, Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011336
DOI https://dx.doi.org/10.2174/1389450111007011336 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Recent Progress in Radiofluorination of Peptides for PET Molecular Imaging
Current Organic Synthesis Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Multiple Hsp70 Isoforms in the Eukaryotic Cytosol: Mere Redundancy or Functional Specificity?
Current Genomics Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design Reactivity-Based Drug Discovery Using Vitamin B6-Derived Pharmacophores
Mini-Reviews in Medicinal Chemistry Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism Thiol Proteases: Inhibitors and Potential Therapeutic Targets
Current Medicinal Chemistry Phosphonium Salt Displays Cytotoxic Effects Against Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry In Vitro Anticancer Evaluation of Some Synthesized 2H-Quinolinone and Halogenated 2H-Quinolinone Derivatives as Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Classifications and Clinical Assessment of Haemorrhoids: The Proctologist’s Corner
Reviews on Recent Clinical Trials Some Wild-Growing Plant Species from Serbia and Montenegro as the Potential Sources of Drugs
Current Pharmaceutical Design Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry